Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

Proposal Announcement by Berenberg Bank, Davy Research, Deutsche Bank, Morgan Stanley and UBS;

(v)  calculation of Broker Projected Revenue from third party reports – the median of revised revenue forecasts sourced from broker reports published following the announcement of the Tysabri Transaction on February 6, 2013 and prior to the Proposal Announcement by Berenberg Bank, Cowen, Davy Research, Deutsche Bank, Morgan Stanley, RBC Capital Markets and UBS;

(vi)  calculation of median projected EBITDA, earnings per share and revenue multiples for the Large Cap Biotech Companies and the Specialty Pharma Companies is based on multiples sourced from I/B/E/S consensus as downloaded from FactSet on February 22, 2013, FactSet on February 22, 2013 (for share prices and numbers of shares outstanding) and company filings (for balance sheet data);

(vii)  Biogen's presentation made to investors on February 6, 2013 following the announcement of the Tysabri Transaction;

(viii)  CallStreet transcript of Tysabri Conference Call on February 6, 2013;

(ix)  Elan's 20-F SEC filing on February 12, 2013 for the financial year ended December 31, 2012; and

(x)  Alkermes plc (ALKS) 13-D SEC filing on February 6, 2013.

J.P. Morgan is lead financial advisor to Royalty Pharma with BofA Merrill Lynch and Groton Partners acting as co-advisors.

This announcement does not amount to a firm intention to announce an offer and there can be no certainty that an offer will be forthcoming (even if the pre-conditions noted above are satisfied or waived) or, if made, as to the conditions of any offer.ENQUIRIES
Royalty Pharma
Pablo Legorreta
George Lloyd
Tel: +1 212 883 2275

J.P. Morgan  (lead financial advisor)
Henry Gosebruch (New York, Tel: +1 212 270 6000)
Dwayne Lysaght / James Mitford (London, Tel: +44 (0) 20 7742 4000)

BofA Merrill Lynch (financial advisor)
Ivan Farman (N
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)...  Personal Genome Diagnostics Inc. (PGDx), today announced ... expertise in genomic analysis of defined cancer subtypes ... Blueprint Medicines.  PGDx is an innovator in conducting ... tumors, and Blueprint Medicines is an expert in ... defined patient population. "This collaboration brings ...
(Date:5/21/2013)... 2013 Revolutionary Science, the manufacturer of ... announced today that they have expanded their colony counter ... IncuCount, IntelliCount, InCount and ImpressCount. These affordable colony ... useful in food microbiology and pharmaceutical manufacturing. , The ... A bright white enclosure with jet black accents ...
(Date:5/21/2013)... Mississauga, Ontario (PRWEB) May 21, 2013 ... expert scientists of the ITN to design the ... usefulness of two key clinical models used in ... Chamber (EEC) and Nasal Allergen Challenge (NAC) models. ... supported by numerous publications, to date no direct ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... HARBIN, China, April 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... CSKI ), a,leading fully integrated pharmaceutical company ... today announced record,financial results for the fourth quarter and ... Fourth Quarter 2008 Highlights, -- ...
... Inc. (Nasdaq: VTIV ) today announced that it ... conference call on Friday, May 8, 2009 at 8:30 a.m. ... listen, please dial 800-358-8448 (Domestic) or (706) 634-1367 (International). The ... at http://www.inventivhealth.com/about_us/n_webcasts.aspx . To listen, ...
... OmniComm Systems, Inc. (OTC Bulletin Board: OMCM) announced that ... LLC for the purpose of resolving the patent infringement ... entered into a licensing arrangement with DataSci. OmniComm ... have come to an agreement in this matter. ...
Cached Biology Technology:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 2China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 4China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 5China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 6China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 7China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 8China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 9China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 10inVentiv Health to Announce First Quarter 2009 Results and Conduct Conference Call on Friday, May 8 2OmniComm Systems Announces Settlement of Patent Litigation With DataSci, LLC 2
(Date:5/21/2013)... the body, stem cells in the blood often ... mature immune cells that can fight off illness. ... cell populations, potentially leading to the development of ... team of researchers led by biologists at the ... in mouse models, the molecule microRNA-146a (miR-146a) acts ...
(Date:5/21/2013)... Cancers of all types become most deadly when ... cancer has reached this stage, it becomes very difficult ... that can develop. Now, researchers at the University of ... that target lymphoma tumor cells wherever they may be ... oncology in the MU College of Veterinary Medicine, says ...
(Date:5/21/2013)... College of Medicine will study gender differences in how the ... -- and how changes in fat metabolism play a role ... from the National Heart, Lung and Blood Institute. , When ... These changes may play a major role in the development ... says E. Douglas Lewandowski, director of the UIC Center for ...
Breaking Biology News(10 mins):Keeping stem cells strong 2MU researchers develop radioactive nanoparticles that target cancer cells 2Do men's and women's hearts burn fuel differently? 2
... Some bacteria react to the cold by subtly changing the ... as temperatures drop. Scientists identified a key protein in this ... how bacteria sense cold in the first place remained a ... and Argentina,s National University of Rosario, the answer is: They ...
... species may play highly important but vastly underrecognized ... group of evolutionary biologists suggests in a study. ... may be forcing these mutualist systems down unprecedented ... change can happen very rapidly, over a few ...
... hold increasing promise as a cure for multiple diseases. But ... flip side, as faulty regulation of stem cells leads to ... made by the stem cells of the foetus are a ... by the body losing control of stem cell function. Guiding ...
Cached Biology News:Bacteria gauge cold with molecular measuring stick 2From bees to coral reefs: How humans impact partnerships in the natural world 2From bees to coral reefs: How humans impact partnerships in the natural world 3From bees to coral reefs: How humans impact partnerships in the natural world 4From bees to coral reefs: How humans impact partnerships in the natural world 5Shock tactics: Bioelectrical therapy for cancer and birth defects? 2
Reacts with methylated DNA from plants and vertebrates...
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: